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1. Introduction 
Tuberculosis (TB) is an international infectious disease problem, but people in the 
developing countries are the major sufferers (World Health Organization, 2010). The disease 
in humans is primarily caused by a pathogenic mycobacterial species known as 
Mycobacterium tuberculosis. The current estimates suggest that about 1/3rd of the world 
population is latently infected with M. tuberculosis, 9 million people develop the active 
disease and 1.7 million die of TB each year (World Health Organization, 2009). Among 
infectious diseases, TB is the second top most killer of adults, after HIV/AIDS, and is among 
the overall top 10 causes of death in the world (World Health Organization, 2008).  The 
global problem of TB is so serious that it has been declared “a global emergency” by the 
World Health Organization (WHO), the first declaration of its kind by WHO. Several factors 
have contributed in the deterioration of the global problem of TB, which include the increase 
in the incidence of drug-resistant TB (multi and extensive drug resistance), migration of 
people, due to political and economic reasons, from poor and highly endemic countries to 
countries with low endemicity, and co-infection with M. tuberculosis and HIV (Borgdorff et 
al., 2010; Chiang et al., 2010; Semba et al., 2010). The worldwide control of TB requires cost-
effective, sensitive and specific methods to diagnose latent as well as active TB, and vaccines 
that can provide protection in all human populations irrespective of their immune status, 
geographical locations and environmental conditions (Mustafa, 2009, 2010).  
Tuberculin skin test (TST) is considered the standard test for the diagnosis of infection with 
M. tuberculosis. The test involves intradermal injection of purified protein derivative (PPD), 
which is a poorly defined and crude mixture of secreted and somatic proteins present in the 
culture filtrate of M. tuberculosis. For TST, PPD is injected in the forearm and the ensuing 
delayed type hypersensitivity (DTH) skin reaction (induration) is read after 48 to 72 h. A 
DTH reaction with induration of 10 mm or greater is considered positive in 
immunocompetent subjects (Mahadevan et al., 2005; Moffitt & Wisinger, 1996). Although, 
PPD has been used for TB diagnosis and epidemiological studies for more than half a 
century, it cannot distinguish between active disease, prior sensitization by contact with M. 
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tuberculosis, BCG vaccination, or cross-sensitization by environmental mycobacteria (Hill et 
al., 2006; Leung et al., 2005). This is because PPD contains a large number of mycobacterial 
antigens (>200), some of which are shared among all the pathogenic mycobacteria belonging 
to the M. tuberculosis complex (M. tuberculosis, M. bovis, and M. africanum), environmental 
non-tuberculous mycobacteria (NTM), and the substrains of M. bovis bacille Calmette-Guerin 
(BCG) vaccines. Thus, although response to PPD is an important aid in the diagnosis of TB 
and can give an indication of exposure to mycobacteria, it is often impossible to distinguish 
BCG vaccination and exposure to NTM from M. tuberculosis infection. Thus, TST has poor 
diagnostic value, especially in geographic areas where BCG vaccine is routinely used or the 
environmental burden of non-tuberculous mycobacteria is high (Kurup et al., 2006). 
Therefore, there is a need to identify and produce M. tuberculosis-specific antigens, which 
can be useful as skin test reagents for specific detection of infection with M. tuberculosis. 
Vaccination is considered the most important tool to provide protection against TB, and 
attempts have been made to vaccinate humans, against TB, since the discovery of the TB 
bacillus by Koch in 19th century. However, the best vaccine available till date is the live 
attenuated strain of M. bovis, i.e. BCG, developed by Calmette and Guerin in 1921. Since 
then BCG has been used as a vaccine to prevent TB. In spite of its widespread application 
for about 90 years and many advantages like being inexpensive, safe at birth, given as a 
single shot, and provision of some protection against childhood TB and severe 
manifestations of the disease (Trunz et al., 2006), BCG vaccine remains the most 
controversial vaccine in current use (Fine, 2001). This is because its protective efficacy has 
varied widely in different parts of the world (Haile & Kallenius, 2005). In particular, BCG 
has failed to provide protection in developing countries against pulmonary TB, the most 
common manifestation of TB, in adults (Crampin et al., 2009; Narayanan, 2006). 
Furthermore, the widespread use of BCG vaccination faces two additional problems. First is 
the interference with TST in the diagnosis of TB because BCG vaccination induces a DTH 
response that cannot be distinguished from infection with M. tuberculosis, and therefore it 
becomes difficult to use TST for diagnostic or epidemiological purposes (Mustafa & Al-
Attiyah, 2003). Second, BCG, being a live vaccine, cannot be used in all groups of people 
because it may cause disease by itself in immunocompromised people (Hesseling et al., 
2007). The WHO has recommended that children with symptoms of HIV or AIDS should 
receive all the vaccines except BCG (World Health Organization, 2007). An ideal vaccine 
against TB should be safe and induce protective immunity both in immunocompetent and 
immunocompromised individuals. The development of a better BCG vaccine or alternative 
vaccines requires the identification and production of M. tuberculosis-specific antigens 
recognized by protective immune responses.  
2. Identification of M. tuberculosis-specific genomic regions and encoded 
antigens 
The existence of three M. tuberculosis / M. bovis-specific genomic regions deleted in BCG, i.e. 
regions of difference (RD)1, RD2 and RD3, was first described by Mahairas et al. in 1996 by 
employing subtractive genomic hybridization to identify genetic differences between M. 
tuberculosis, M. bovis and BCG (Mahairas et al., 1996; Table 1). Later, in 1999, studies using 
comparative genome analysis identified 16 RDs that were present in M. tuberculosis H37Rv 
(RD1 to RD16) but deleted/absent in some or all strains of M. bovis and/or BCG (Behr et al., 
1999; Table 1). Among these, 11 regions (RD1, RD4 to RD7, RD9 to RD13 and RD15) 
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covering 91 open reading frames (ORFs) of M. tuberculosis H37Rv were deleted from all 
vaccine strains of BCG (Table 1). It was suggested that the identification of antigens encoded 
by the genes in M. tuberculosis-specific RDs may identify new M. tuberculosis-specific 
antigens with diagnostic and /or vaccine potential (Mustafa, 2001, 2002). 
 
RD 
designation 
No. 
of 
ORFs
ORFs designation 
ORFs deleted / absent in 
M. bovis 
strains 
BCG strains 
RD1 
8 
9 
14 
ORF1A-ORF1K 
Rv3871-Rv3879 
ORF2-ORF15 
 
Not deleted All strains 
RD2 11 Rv1978-Rv1988 Not deleted 
Connaught , Danish, 
Frappier, Glaxo, Pasteur, 
Phipps,  Prague, Tice 
RD3 14 
Rv1573-Rv1586c 
 
3/8 All strains 
RD4 3 Rv0221-Rv0223c 8/8 All strains 
RD5 5 Rv3117-Rv3121 8/8 All strains 
RD6 11 Rv1506c-Rv1516c 8/8 All strains 
RD7 8 Rv2346c-Rv2353c 8/8 All strains 
RD8 4 Rv0309-Rv0312 Not deleted Connaught, Frappier 
RD9 7 Rv3617-Rv3623 8/8 All strains 
RD10 3 Rv1255c-Rv1257c 8/8 All strains 
RD11 5 Rv3425-Rv3429 8/8 All strains 
RD12 4 Rv2072c-Rv2075c 8/8 All strains 
RD13 16 Rv2645-Rv2660c 4/8 All strains 
RD14 8 Rv1766-Rv1773c Not deleted Pasteur 
RD15 15 Rv1963c-Rv1977 8/8 All strains 
RD16 6 Rv3400-Rv3405c Not deleted Moreau 
Table 1. Designation of M. tuberculosis RDs deleted/absent in M. bovis and/or BCG, the 
number of ORFs predicted in each ORFs designations. 
To analyze the M. tuberculosis-specific RDs for cell mediated immune (CMI) responses 
involving T helper (Th)1 cells that are associated with protection against TB, a novel 
approach of overlapping synthetic peptides was used (Al-Attiyah & Mustafa, 2008). Each 
peptide was 25 aa in length and overlapped with the neighboring peptides by 10 aa. Since 
the length of Th1 cell epitopes is usually between 8 to 10 aa (Mustafa, 2000, 2005a), the 
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overlapping synthetic peptide strategy minimized the possibility of missing the potential 
Th1 cell epitopes. A total of 1648 peptides were synthesized and peptide pools 
corresponding to each RD were tested for reactivity with human PBMC in Th1-cell assays, 
i.e. antigen-induced proliferation and IFN-γ฀secretion. The results showed that RD1 was the 
most important region encoding proteins with Th1-cell reactivity (Al-Attiyah & Mustafa, 
2008, 2010; Mustafa & Al-Attiyah, 2009; Mustafa et al., 2011). The analysis of individual 
peptide pools of RD1 ORFs identified three major (Rv3873, Rv3874 and Rv3875) and three 
moderate (Rv3871, Rv3872 and Rv3876) antigens stimulatory for Th1 cells in antigen-
induced proliferation and IFN-γ฀assays (Hanif et al., 2008; Mustafa 2005b; Mustafa et al., 
2008). However, Rv3873 and Rv3876 proteins were equally good stimulators of Th1 cells 
from TB patients and healthy donors, whereas Rv3872, Rv3874, Rv3875 proteins were better 
stimulators in TB patients and Rv3871 protein in healthy donors (Mustafa et al., 2008). When 
tested with PBMC in a cattle model of TB, Rv3872, Rv3873, Rv3874 and Rv3875 were also 
found to be major to moderate stimulators of Th1 cells present in the peripheral blood of M. 
tuberculosis-infected Cattle (Mustafa et al., 2002). The overall results showed that M. 
tuberculosis-specific proteins of RD1 Rv3872, Rv3873, Rv3874 and Rv3875 are major Th1-cell 
antigens and therefore could be useful as antigens in specific diagnosis and developing new 
vaccines against TB. However, for these applications, it was essential that the genes 
encoding these proteins are cloned and expressed in suitable vectors and the recombinant 
proteins are obtained in a purified form. 
The predictions for all ORFs with Rv numbers are according to the predictions of Behr et al. 
(Behr et al., 1999), whereas RD1 ORF1A to ORF1K and ORF2 to ORF15 are according to the 
predictions of Mahairas et al. and Mustafa, respectively (Mahairas et al., 1996; Mustafa, 
2005c). These RDs are expected to encode a total of 134 ORFs, of which 91 ORFs are 
predicted in RD1, RD4 to RD7, RD9 to RD13 and RD15, which are present in all strains of M. 
tuberculosis, but  absent/deleted in all strains of BCG (Mustafa, 2001). RD3, although deleted 
in all BCG strains, is also deleted from some clinical strains of M. tuberculosis as well (Behr et 
al., 1999). 
3. Molecular cloning, expression, purification and immunological 
characterization of proteins encoded by RD genes 
In order to immunologically characterize the putative RD proteins encoded by M. 
tuberculosis-specific genes deleted/absent in BCG, previous studies attempted to clone and 
express six ORFs of RD1, i.e. ORF10 to ORF15 (Amoudy et al., 2006), as recombinant 
proteins in E. coli. However, these studies were successful in expressing five of the six 
targeted proteins as fusion proteins, fused with glutathione S-transferase (GST), by using the 
commercially available pGEX-4T vectors, but only two of them could be purified using 
glutathione-Sepharose affinity columns (Ahmed et al., 1999a, Amoudy et al., 2007; Amoudy 
& Mustafa, 2008). The problems included degradation of the mycobacterial proteins, non-
binding of fusion proteins to affinity columns and the presence of contaminating E. coli 
proteins in purified preparations (Ahmed et al., 1999b, Amoudy & Mustafa, 2008). These 
studies have shown that even though high level expression of several mycobacterial 
proteins could be achieved by fusing them with GST, their purification was unsatisfactory 
and sometimes difficult due to improper folding of the fusion proteins and co-elution of E. 
coli proteins from the column along with the mycobacterial proteins. This is mainly due to 
the fact that the binding of GST containing fusion proteins on glutathione-Sepharose column 
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is dependent on the proper folding of the GST tag and some E. coli proteins bind to the 
column non-specifically. However, binding of proteins fused with the 6x His tag to Ni-NTA 
agarose is not affected by the conformation of the expressed proteins and, consequently, 
proteins containing this tag can be purified even under denaturing conditions (Hendrickson 
et al., 2000). Therefore a new vector, pGES-TH-1, was developed using pGEX-4T-1 vector as 
the backbone (Ahmad et al., 2003). In addition to the features offered by the pGEX-4T 
vectors for high level expression of fusion proteins, the new vector was expected to allow 
relatively easy purification of recombinant proteins on the highly versatile Ni-NTA-agarose 
affinity matrix. The experimental utility of the new vector was demonstrated by expressing 
and purifying to homogeneity two proteins of RD1 (Rv3872 and Rv3873) and three proteins 
of RD15 (Mce3A, Mce3D and Mce3E) of M. tuberculosis (Ahmad et al., 2003, 2004, 2005). All 
these proteins were expressed in E. coli, in fusion with GST. The recombinant RD proteins 
were purified and isolated, free of GST, by affinity purification on glutathione-Sepharose 
and/or Ni-NTA-agarose affinity matrix and cleavage of the purified fusion proteins by 
thrombin protease. All recombinant proteins were more than 90% pure and were 
immunologically reactive with antibodies present in sera of TB patients and/or immunized 
animals (Ahmad et al., 2003, 2004, 2005; El-Shazly et al., 2007). These results demonstrated 
the utility of the newly constructed pGES-TH-1expression vector with two affinity tags for 
efficient expression and purification of recombinant RD proteins expressed in E. coli, which 
could be used for further diagnostic and immunological investigations both in animals as 
well as in humans. 
In a recent study, we extended the work to achieve high level expression and 
purification of three low molecular weight proteins encoded by M. tuberculosis-specific 
genomic regions of RD1 and RD9, i.e. Rv3874, Rv3875 and Rv3619c, using the pGES-TH-
1 expression vector (Hanif et al., 2010a). The complete cloning, expression and 
purification strategy for these proteins is shown in figure 1, by using Rv3875 as an 
example (Fig. 1). In brief, DNA corresponding to each gene was amplified using gene-
specific forward (F) and reverse (R) primers and genomic DNA of M. tuberculosis by 
polymerase chain reaction (PCR). In addition to gene-specific sequences, in order to 
facilitate cloning in the pGEST-TH-1 vector, the F and R primers had BamH 1 and Hind 
III restriction sites at their 5’ ends, respectively. The PCR-amplified DNA were analyzed 
by agarose gel electrophoresis, which showed the amplified fragments corresponded to 
the size of the respective genes. The PCR-amplified DNA were ligated to pGEM-T Easy 
vector DNA, yielding recombinant plasmids pGEM-T/Rv3874, pGEM-T/Rv3875 and 
pGEM-T/Rv3619c. The identities of the cloned DNA fragments were determined based 
on size by digestion of the recombinant plasmids with EcoR I. Furthermore, The DNA 
fragments corresponding to rv3874, rv3875 and rv3619c genes were excised from 
recombinant pGEM-T Easy using the restriction enzymes BamH 1 and Hind III and 
subcloned in the expression vector pGES-TH-1, which was predigested with the same 
restriction enzymes. The identity of each gene in recombinant pGES-TH-1 was confirmed 
by restriction digestion and DNA sequencing. E. coli cells were transformed with 
recombinant pGES-TH-1 and induced for the expression of fusion proteins, which were 
detected by sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS–PAGE) 
using lysates of induced E. coli cells. The results showed the expression of proteins that 
corresponded to the size of GST/Rv3874, GST/Rv3875 and GST/Rv3619c. The identity of 
the expressed fusion proteins was established by Western immunoblotting with anti-GST 
and anti-penta His antibodies.  
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The SDS–PAGE analysis of cell-free extracts and pellets of sonicates of induced E. coli cells 
containing pGES-TH/Rv3874, pGES-TH/Rv3875 and pGES-TH/Rv3619c showed that 
recombinant GST-Rv3874 and GST-Rv3875 proteins were present in the soluble fraction, 
whereas the recombinant GST-Rv3619c protein was present in the pellet, which could be 
solublized best in 4 M urea. To purify the recombinant RD proteins, the soluble/solublized 
fractions were loaded on to glutathione-Sepharose affinity matrix and the GST-free RD 
proteins were released from the GST fusion partner bound to the column matrix by cleavage 
with the enzyme thrombin protease. The cleaved RD proteins were eluted and analyzed for 
purity by SDS–PAGE and staining with Coomassie Blue. The results showed that the 
recombinant Rv3874 and Rv3875 proteins were contaminated with another protein of nearly 
70 kDa, whereas Rv3619c protein was nearly homogeneous (more than 95% pure). The 
partially purified Rv3874 and Rv3875 proteins were further purified on Ni-NTA agarose 
affinity matrix, and the analysis of eluted fractions showed the presence of a single sharp 
band in SDS–PAGE gels, which suggested that Rv3874 and Rv3875 preparations became free 
of the 70-kDa contaminant and were nearly homogeneous (more than 95% pure) (Hanif et 
al., 2010a). These results further strengthen the suggestion that pGES-TH-1 is useful for high 
level expression and efficient purification of recombinant mycobacterial proteins (Ahmed et 
al., 2003; 2004). The reason for Rv3619c requiring only one column (glutathione-Sepharose) 
for purification could be the presence of the fusion protein GST-Rv3619c in the pellet of 
induced E. coli cultures, which lacked the contaminating E. coli protein of 70 kDa. On the 
other hand, GST-Rv3874 and GST-Rv3875 proteins were present in the soluble fraction that 
also contained E. coli protein of 70 kDa, which was capable of binding to glutathione-
Sepharose column nonspecifically, and was eluted from the column along with Rv3874 and 
Rv3875. However, the subsequent use of Ni-NTA matrix efficiently removed the 
contaminating E. coli protein and made the recombinant Rv3874 and Rv3875 proteins 
homogeneously pure (Hanif et al., 2010a). 
The immunogenicity of all the three pure recombinant proteins (Rv3874, Rv3875 and Rv3619c) 
was evaluated in rabbits. The animals were immunized with the purified RD proteins and the 
sera were tested for antibody reactivity with the full-length recombinant proteins, pools of 
synthetic peptides covering the sequence of each protein and their individual peptides, as 
described previously (Hanif et al., 2010a). In brief, polyclonal antibodies were raised in rabbits 
against the purified and GST-free Rv3874, Rv3875 and Rv3619c recombinant proteins by 
emulsifying purified proteins (50 μg/ml) with an equal volume of incomplete Freund’s 
adjuvant and injected intramuscularly in the right and left thigh. The rabbits were boosted 
twice with the same amount of protein at 2 weeks intervals. The animals were bled from the 
ear vein before the immunization and 2 weeks after the last immunization. The sera were 
tested for antigen-specific antibodies using Western immunoblotting. The results showed that 
pre-immunized rabbit sera did not have antibodies to any of these proteins, and the sera from 
immunized rabbits had antibodies reactive with the immunizing proteins only, thus 
confirming the specificity of the polyclonal antibodies to the immunizing antigens. In addition, 
the results suggested that the rabbits used were not exposed to M. tuberculosis and the 
antibody epitopes of a given protein were not crossreactive with other proteins. Moreover, 
ELISA was performed to detect antibodies in rabbit sera against full-length purified 
recombinant proteins and overlapping synthetic peptides corresponding to each protein. The 
ELISA results further showed specificity of the antibody reactivity with the immunizing 
proteins and positivity with synthetic peptides, which suggested that linear epitopes of each 
protein were recognized by B cells, after immunization with full-length proteins. Furthermore, 
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testing of sera with individual peptides of each protein demonstrated that rabbit antibodies 
recognized several linear epitopes that were scattered throughout the sequence of each protein 
(Hanif et al., 2010a). Interestingly, previous studies using pools of synthetic peptides have 
shown that all of these proteins (Rv3874, Rv3875 and Rv3619c) are major T cell antigens in 
humans, and the linear T cell epitopes were scattered throughout the sequence of these 
proteins (Hanif et al., 2008; Mustafa et al. 2000, 2003, 2008). A further analysis of the sequence 
of these proteins for B cell and T cell epitope prediction using appropriate prediction servers 
further suggested that B-cell and T-cell epitopes were scattered throughout the sequence of 
each protein (Hanif et al., 2010a; Mustafa et al., 2008; Mustafa and Shaban, 2006). Thus, both 
prediction and experimental results confirm the strong immunogenicity of Rv3874, Rv3875 
and Rv3619c proteins for inducing antigen-specific immunological reactivity.  
 
 
Fig. 1. Strategy and the schematic presentation of the steps involved in the cloning of rv3875 
gene in pGES-TH-1 vector, followed by expression of the fusion protein (GST-Rv3875) and 
purification of GST-free recombinant Rv3875 protein. 
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4. Potential of the purified recombinant RD proteins as M. tuberculosis-
specific skin test antigens  
Although, PPD in tuberculin skin test has been widely used as a diagnostic and 
epidemiological tool for tuberculosis monitoring in humans and animals for many 
years, there are many practical and theoretical problems related to the skin test, as 
stated above in the introduction of this chapter. To overcome the antigenic 
crossreactivity of PPD, we have tested four purified recombinant RD1 proteins (Rv3872, 
Rv3873, Rv3874, Rv3875) and one RD9 protein (Rv3619c) of M. tuberculosis for their 
ability to induce DTH skin responses in guinea pigs immunized with M. tuberculosis 
(Hanif et al., 2010b). Like RD1, RD9 is also a region that has been suggested to be 
deleted in all strains of BCG (Behr et al., 1999). However, using overlapping synthetic 
peptides, Rv3619c protein has been previously shown to induce moderate T-cell 
responses both in TB patients and healthy subjects (Mustafa and Al-Attiyah, 2004). 
Furthermore, Rv3619c belongs to the same family of proteins as Rv3874 and Rv3875 of 
RD1, i.e. ESAT6-family (Mustafa and Al-Attiyah, 2004). The evaluation of these proteins 
for induction of DTH responses as well as their specificity to M. tuberculosis-injected 
animals is important in the context of their potential usefulness as reagents for specific 
diagnosis to replace PPD, which has both M. tuberculosis-specific as well as crossreactive 
antigens. 
In order to investigate the diagnostic potential of the purified recombinant proteins 
Rv3872, Rv3873, Rv3874, Rv3875, and Rv3619c, DTH skin responses were studied in 
guinea pigs injected with heat killed M. tuberculosis and live BCG, M. avium and M. vaccae. 
Two to four weeks later, the guinea pigs were challenged intradermally in the flank 
region with 1 µg of mycobacterial sonicates and purified recombinant proteins. The DTH 
responses were quantitated by measuring erythema at the sites of injections after 24 h. 
The results showed that all mycobacterial sonicates induced positive DTH responses in M. 
tuberculosis, BCG, M. avium and M. vaccae injected guinea pigs, which, like PPD, have 
crossreactive antigens. The purified recombinant proteins Rv3872, Rv3873, Rv3874 and 
Rv3875 elicited positive DTH responses in M. tuberculosis injected group, but not in BCG, 
M. avium and M. vaccae injected guinea pigs; whereas Rv3619c elicited positive DTH 
responses in M. tuberculosis and BCG injected animals but not in M. avium and M. vaccae 
injected guinea pigs (Hanif et al., 2010b). These results confirm the expression of all the 
proteins in M. tuberculosis and furthermore demonstrate their in vivo immunogenicity in 
guinea-pigs, which is the most sensitive animal model of TB. In addition, the induction of 
species-specific DTH responses suggests that the use of M. tuberculosis-specific 
recombinant RD1 antigens (Rv3872, Rv3873, Rv3874 and Rv3875) may lead to the 
development of DTH skin tests that can differentiate between tuberculous infection verses 
BCG vaccination and exposure to environmental mycobacterial species of M. avium and 
M. vaccae. In addition, the use of M. tuberculosis complex-specific Rv3619c protein in skin 
tests may differentiate between infection with M. tuberculosis and BCG vaccination verses 
exposure to environmental mycobacteria. However, these suggestions should be 
followed-up and studies should be extended to natural hosts of TB, including humans, for 
evaluation of the identified recombinant proteins as species-specific skin test antigens to 
replace PPD. 
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5. Cloning, expression and immunogenicity of RD genes in DNA vaccine 
vectors 
The failure of BCG vaccine in humans has prompted the research to develop alternative 
vaccines against TB. Among the novel vaccine candidates, plasmid DNA-based TB vaccines 
have drawn close attention because of their unique features compared to conventional live 
or subunit vaccines, including induction of strong Th1 based CD4+ responses as well as 
cytotoxic T cell responses (Huygen, 2006). Therefore potency of plasmid DNAs expressing a 
variety of immunogenic M. tuberculosis antigens has been intensively evaluated in the past 
(Romano & Huygen., 2009). Unfortunately, their performance is generally not superior to 
BCG, especially in large animals. However, the licensure of a DNA vaccine in horses 
highlights the potential of DNA vaccine technology in the prevention of TB infection (Ulmer 
et al., 2006). Besides, it is generally believed that novel TB vaccines will be tested in the 
context of the widely used BCG and perhaps different kinds of vaccines are needed for the 
eradication of TB (Mitsuyama & McMurray, 2007; Sander & McShane, 2007). As a result, 
enhancement of TB DNA vaccine efficacy has become the active field of current research 
(Okada & Kita, 2010). In this context, Baldwin et al. have shown that inclusion of the 
secretion signal peptide from tissue plasminogen activator (tPA) into a DNA vaccine 
construct resulted in stronger immune responses to Ag85A, and provided sustained 
protection upon M. tuberculosis challenge in mice, as compared to the DNA vaccine 
construct based on the parent plasmid lacking tPA (Baldwin et al., 1999). Furthermore, a 
plasmid DNA vaccine expressing the heat shock protein 65 (HSP65-DNA vaccine) provided 
improved protective and therapeutic effects in mice when fused with human interleukin-2 
(hIL-2) (Changhong et al., 2009).  
To further study and compare the effect of tPA and hIL-2, we have used two plasmid 
vectors i.e. pUMVC6 and pUMVC7, to clone and express M. tuberculosis-specific RD proteins 
and studied antigen-specific cellular immune responses after immunization of mice with the 
recombinant plasmids (Hanif et al., 2010c). The plasmid vectors pUMVC6 and pUMVC7 are 
eukaryotic expression vectors, which have been prepared by University of Michigan Vector 
Core (UMVC) and made commercially available by Aldevron, USA. Both vectors have CMV 
promoter at 5’ end of the cloning site (Figs. 2, 3). pUMVC6 is characterized by having a 
secretion signal peptide from hIL-2 (hIL2 secretory peptide) as an immuno-stimulatory 
sequence (Fig. 2), whereas pUMVC7 has a signal peptide for targeting peptides to a 
secretory pathway by fusion to the tPA signal peptide (Fig. 3).  
To prepare DNA vaccine constructs using the above plasmids, DNA fragments 
corresponding to five RD genes, i.e. rv3872 (pe35), rv3873 (ppe68), rv3874 (esxA), rv3875 (esxB) 
and rv3619c (esxV), were PCR amplified from genomic DNA of M. tuberculosis by using 
gene-specific forward (F) and reverse (R) primers. To facilitate cloning of PCR amplified 
DNA in pUMVC6 and pUMVC7 vectors, in addition to gene-specific sequences, the F and R 
primers had appropriate restriction sites at 5’ ends, i.e. BamH I and BamH I, and BamH I and 
Xba I restriction sites for pUMVC6 and pUMVC7, respectively. The amplified DNA were 
first cloned into pGEM-T Easy vector, before subcloning into pUMVC6 and pUMVC7 (Figs. 
2, 3 with Rv3875 DNA shown as an example). This was done to facilitate the subcloning of 
appropriate DNA into the eukaryotic expression vectors pUMVC6 and pUMVC7, as has 
been demonstrated previously for prokaryotic expression vectors pGEX-4T and pGES-TH-1 
(Ahmed et al., 1999b, 2003; Hanif et al., 2010a). The cloning in pGEM-T Easy successfully 
yielded five recombinant plasmids, one for each gene, i.e. pGEM-T/Rv3872, pGEM- 
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Fig. 2. The strategy and schematic presentation of the steps involved in the construction of 
recombinant plasmid pUMVC6/Rv3875, purification of recombinant plasmid DNA on a 
large scale. 
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Fig. 3. The strategy and schematic presentation of the steps involved in the construction of 
recombinant plasmid pUMVC7/Rv3875, purification of recombinant plasmid DNA on a 
large scale. 
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T/Rv3873, pGEM-T/Rv3874, pGEM-T/Rv3875 and pGEM-T/Rv3619c. The analysis of 
DNA fragments released from the recombinant pGEM-T Easy plasmids after digestion with 
EcoR I showed that the cloned DNA corresponded to the expected molecular size of rv3872, 
rv3873, rv3874, rv3875 and rv3619c genes. To prepare DNA vaccine constructs, the 
recombinant pGEM-Ts were single digested with BamH I for subcloning into pUMVC6 and 
double digested with Bam HI and Xba I for subcloning into pUMVC7. These restriction 
digestions released the DNA fragments corresponding to rv3872, rv3873, rv3874, rv3875 and 
rv3619c genes with BamH I/BamH I and BamH I/Xba I cohesive ends. All the genes were 
subcloned into plasmid vectors by their ligation to pUMVC6 and pUMVC7 DNA 
predigested with BamH I/BamH I and BamH I/Xba I, respectively. The identity of each 
cloned gene was determined by restriction digestion of recombinant plasmids with the 
restriction enzymes BamH I for pUMVC6; and BamH I and Xba I for pUMVC7, which 
released the cloned DNA corresponding to the size expected for each gene. E. coli cells were 
transformed with the parent and recombinant pUMVC6 and pUMVC7 plasmids, and large 
quantities of the plasmids were purified from the transformed E. coli cells grown in vitro by 
using Qiagen Endofree Mega kits (Qiagen, Valencia, CA, USA) according to the 
manufacturer’s instructions. The overall strategies of gene amplification, cloning and large-
scale purification of recombinant pUMVC6 and pUMVC7 plasmid DNA are shown in 
figures 2 and 3, respectively, using rv3875 as an example (Fig. 2, 3). In this way, a total of 10 
recombinant DNA plasmids (five for each vector) were constructed (Hanif et al., 2010c). 
To study the expression and immunogenicity of the RD1 and RD9 proteins cloned in the 
recombinant vaccine constructs of pUMVC6 and pUMVC7, immunization studies were 
performed in mice. Groups of 6–8 week old BALB/c mice (five mice in each group) were 
immunized intramuscularly with three doses of purified parent or recombinant plasmid 
DNA, each dose containing 100 μg of DNA, and given 3 weeks apart. After 3 weeks of the 
third immunization, spleen cells were isolated from each immunized mouse for cellular 
immune responses using antigen-induced proliferation as an indicator (Hanif et al., 2010c). 
The results demonstrated that spleen cells of mice un-immunized or immunized with the 
parent plasmids did not show positive antigen-induced proliferation responses to any of the 
antigens corresponding to the cloned genes (Hanif et al., 2010c). The results further showed 
that both the recombinant vectors induced antigen-induced cellular proliferation to Rv3872, 
Rv3874, Rv3875 and Rv3619c proteins. However, antigen-induced proliferation responses 
were observed in response to a given protein only with spleen cells of mice immunized with 
the recombinant DNA vaccine construct expressing that protein, except for Rv3873, which 
failed to induce proliferation responses in animals immunized with pUMVC6/Rv3873 or 
pUMVC7/Rv3873 (Hanif et al., 2010c). Moreover, recombinant pUMCV6 induced relatively 
better responses than recombinant pUMCV7. The improved responses with recombinant 
pUMCV6 suggest that hIL2 secretory protein acted as a better adjuvant and enhanced 
cellular immune responses, assessed by antigen-induced proliferation of spleenocytes, to the 
fused mycobacterial proteins more effectively than the tPA signal peptide. The relevance of 
antigen-specific cellular proliferation induced by DNA vaccine constructs with protection 
against M. tuberculosis challenge has been demonstrated in the mouse model of TB (Fan et 
al., 2009).  
Although, the results of this study, showed induction of antigen-specific cellular immune 
responses to the antigens encoded by genes present in DNA vaccine constructs, are 
interesting; the work should be extended to demonstrate their protective efficacy in 
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challenge experiments, with M. tuberculosis, using various animal models of TB, e.g. mice, 
guinea-pigs, rabbits and monkeys etc. Such vaccines may be useful in both prophylactic and 
therapeutic applications in humans, If found effective in animals. Furthermore, DNA-based 
vaccines expressing M. tuberculosis-specific antigens may even be useful in BCG vaccinated 
subjects as preventive vaccines, because revaccination with BCG has not shown beneficial 
effects (Rodrigues et al., 2005, Roth  et al., 2010), and may even be combined with BCG to 
improve its protective efficacy (Fan et al., 2007).  
6. Conclusions 
The modified pGES-TH-1 expression vector was extremely useful in obtaining highly 
purified recombinant preparations of Rv3872, Rv3873, Rv3874, Rv3875 and Rv3619c proteins 
of M. tuberculosis. All of these recombinant proteins were immunogenic in rabbits and the 
antibody epitopes were scattered throughout the sequence of each protein. These results 
suggest that pGES-TH-1 vector could be employed in obtaining pure recombinant proteins, 
predicted to be encoded by hypothetical genes present in M. tuberculosis-specific genomic 
regions, for their immunological characterization. Furthermore, the induction of species-
specific DTH responses suggests that the use of M. tuberculosis-specific RD1 antigens may 
lead to the development of a DTH skin test that discriminates between tuberculous infection 
verses BCG vaccination and exposure to environmental mycobacteria (M. avium and M. 
vaccae). In addition, the use of M. tuberculosis complex-specific Rv3619c protein in skin tests 
may differentiate between tuberculosis infection and BCG vaccination verses exposure to 
environmental mycobacteria. Furthermore, DNA vaccine constructs encoding RD1 and RD9 
genes induced antigen-specific cellular responses in immunized mice to the respective 
proteins, and thus could be useful as safer vaccines to immunize against TB. However, to 
confirm their usefulness as anti-TB vaccines, further studies with the DNA vaccine 
constructs of pUMVC6 and pUMVC7 may be performed to determine their protective 
efficacy in appropriate animal models of TB (mice, guinea-pigs, rabbits and monkeys etc.) 
after challenging the immunized animals with live M. tuberculosis. 
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